EMD Serono has announced that it will open a research site in Cambridge, Massachusetts to support its research function.
According to the company, the Cambridge laboratory space will accommodate EMD Serono’s US drug discovery activities in neurodegenerative diseases such as multiple sclerosis, which will augment the company’s existing US research in oncology and fertility.
EMD Serono expects to occupy the site with nearly 50 scientists across disciplines, including neurobiology, pharmacology and chemistry, to work at the location.
In 2008, EMD Serono announced a planned expansion of its Billerica laboratory to create a center of excellence in discovery, which is scheduled for completion in 2010. The Cambridge satellite laboratory, which will be approximately 18,000 square feet in size, will address the company’s immediate need to secure necessary laboratory space for its additional scientists as a result of accelerated employee growth, the company added.
Fereydoun Firouz, president and CEO of EMD Serono, said: This research expansion further supports EMD Serono’s commitment to develop and deliver innovative therapies for patients in our areas of focus. EMD Serono is following our outlined strategy to broaden our research capabilities by expanding our footprint in the state of Massachusetts in close proximity to leading academic centers and qualified expertise that can be complementary to our organization and add researchers that can grow with our team.